{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:49:05Z","timestamp":1793969345372,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.lungcan.2022.03.018","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T15:55:42Z","timestamp":1648569342000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma \u2013 Interpretation guidance derived from two randomized EORTC trials"],"prefix":"10.1016","volume":"167","author":[{"given":"Michael","family":"Koller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jammbe Z.","family":"Musoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Tomaszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corneel","family":"Coens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine T.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam A.G.","family":"Sprangers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogens","family":"Groenvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Cocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Velikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Henning","family":"Flechtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bottomley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2022.03.018_b0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2022.03.018_b0010","first-page":"327","article-title":"Global trends of lung cancer mortality and smoking prevalence","volume":"4","author":"Islami","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2022.03.018_b0015","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s10654-016-0207-x","article-title":"Is there more to learn about the epidemiology of lung cancer?","volume":"31","author":"Samet","year":"2016","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.lungcan.2022.03.018_b0020","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1164\/rccm.201507-1420OC","article-title":"The association between smoking abstinence and mortality in the national lung screening trial","volume":"193","author":"Tanner","year":"2016","journal-title":"Am. J. Respiratory Crit. Care Med."},{"key":"10.1016\/j.lungcan.2022.03.018_b0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/aje\/kwt335","article-title":"The 2014 Surgeon General\u2019s report: Commemorating the 50th Anniversary of the 1964 Report of the Advisory Committee to the US Surgeon General and updating the evidence on the health consequences of cigarette smoking","volume":"179","author":"Alberg","year":"2014","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.lungcan.2022.03.018_b0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.path.2016.04.003","article-title":"The molecular pathology of lung cancer","volume":"9","author":"Sholl","year":"2016","journal-title":"Surg. Pathol. Clinics"},{"key":"10.1016\/j.lungcan.2022.03.018_b0035","doi-asserted-by":"crossref","unstructured":"Y. Boss\u00e9, C.I. Amos. A Decade of GWAS Results in Lung Cancer\u00b7 Cancer epidemiology, biomarkers & prevention a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 27 2018 363\u2013379.","DOI":"10.1158\/1055-9965.EPI-16-0794"},{"key":"10.1016\/j.lungcan.2022.03.018_b0040","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/eurpub\/cku145","article-title":"Ambient particulate matter and lung cancer incidence and mortality: a meta-analysis of prospective studies","volume":"25","author":"Cui","year":"2015","journal-title":"Eur. J. Public Health"},{"key":"10.1016\/j.lungcan.2022.03.018_b0045","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1289\/ehp\/1408092","article-title":"Outdoor particulate matter exposure and lung cancer: a systematic review and meta-analysis","volume":"122","author":"Hamra","year":"2014","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.lungcan.2022.03.018_b0050","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.envpol.2017.06.019","article-title":"Air pollution and genomic instability: the role of particulate matter in lung carcinogenesis","volume":"229","author":"Santib\u00e1\u00f1ez-Andrade","year":"2017","journal-title":"Environ. Pollut. (Barking Essex 1987)"},{"key":"10.1016\/j.lungcan.2022.03.018_b0055","doi-asserted-by":"crossref","first-page":"e0192999","DOI":"10.1371\/journal.pone.0192999","article-title":"Lung cancer and socioeconomic status in a pooled analysis of case-control studies","volume":"13","author":"Hovanec","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2022.03.018_b0060","doi-asserted-by":"crossref","unstructured":"K. Welcker. Genderspezifische Unterschiede des Lungenkarzinoms, Zentralblatt f\u00fcr Chirurgie 140 2015 260\u2013265.","DOI":"10.1055\/s-0034-1396231"},{"key":"10.1016\/j.lungcan.2022.03.018_b0065","doi-asserted-by":"crossref","unstructured":"D. Isla, M. Majem, N. Vi\u00f1olas, A. Artal, A. Blasco, E. Felip, P. Garrido, et al. A consensus statement on the gender perspective in lung cancer, Clinical & translational oncology official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico19 2017 527\u2013535.","DOI":"10.1007\/s12094-016-1578-x"},{"key":"10.1016\/j.lungcan.2022.03.018_b0070","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/CMAR.S187317","article-title":"Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades","volume":"11","author":"Lu","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.lungcan.2022.03.018_b0075","doi-asserted-by":"crossref","unstructured":"B. Besse, A. Adjei, P. Baas, P. Meldgaard, M. Nicolson, L. Paz-Ares, M. Reck, et al. 2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line\/second and further lines of treatment in advanced disease, Ann. Oncol. 25 2014 1475\u20131484.","DOI":"10.1093\/annonc\/mdu123"},{"key":"10.1016\/j.lungcan.2022.03.018_b0080","doi-asserted-by":"crossref","unstructured":"W.-L. Tan, A. Jain, A. Takano, E.W. Newell, N.G. Iyer, W.-T. Lim, E.-H. Tan, et al. Novel therapeutic targets on the horizon for lung cancer, Lancet Oncol. 17 2016 e347\u2013e362\u00b71.","DOI":"10.1016\/S1470-2045(16)30123-1"},{"key":"10.1016\/j.lungcan.2022.03.018_b0085","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12032-017-0966-6","article-title":"Progress and challenges in the treatment of small cell lung cancer\u00b7","volume":"34","author":"Tartarone","year":"2017","journal-title":"Med. Oncol. (Northwood, London, England)"},{"key":"10.1016\/j.lungcan.2022.03.018_b0090","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/annonc\/mdv187","article-title":"2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer","volume":"26","author":"Eberhardt","year":"2015","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2022.03.018_b0095","article-title":"Multimodality treatment of advanced non-small cell lung cancer: where are we with the evidence?","volume":"6","author":"Jones","year":"2018","journal-title":"Curr. Surg. Rep."},{"issue":"2","key":"10.1016\/j.lungcan.2022.03.018_b0100","first-page":"82","article-title":"Global mesothelioma epidemic: trend and features Indian","volume":"18","author":"Bianchi","year":"2014","journal-title":"J. Occup. Environ. Med."},{"issue":"18","key":"10.1016\/j.lungcan.2022.03.018_b0105","first-page":"319","article-title":"Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health","volume":"110","author":"Neumann","year":"2013","journal-title":"Dtsch Arztebl Int."},{"issue":"28","key":"10.1016\/j.lungcan.2022.03.018_b0110","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.03.018_b0115","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lungcan.2022.03.018_b0120","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials","volume":"30A","author":"Bergman","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2022.03.018_b0125","doi-asserted-by":"crossref","unstructured":"M. Koller, O. Shamieh, M.J. Hjermstad, et al. Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study. Lancet Oncol. 21(5), 723\u2013732.","DOI":"10.1016\/S1470-2045(20)30093-0"},{"issue":"15","key":"10.1016\/j.lungcan.2022.03.018_b0130","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1200\/JCO.2004.09.147","article-title":"Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module","volume":"22","author":"Nowak","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.03.018_b0135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1475-6773.2005.0k375.x","article-title":"Goodbye M(C)ID! Hello MID, where do you come from?","volume":"40","author":"Sch\u00fcnemann","year":"2005","journal-title":"Health Serv. Res."},{"key":"10.1016\/j.lungcan.2022.03.018_b0140","first-page":"noab037","article-title":"Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients","author":"Dirven","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.lungcan.2022.03.018_b0145","doi-asserted-by":"crossref","unstructured":"J.Z. Musoro, C. Coens, S. Singer, et al. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer [published online ahead of print, 2020 Jul 6]. Head Neck. 2020;10.1002\/hed.26363. doi:10.1002\/hed.26363.","DOI":"10.1002\/hed.26363"},{"key":"10.1016\/j.lungcan.2022.03.018_b0150","doi-asserted-by":"crossref","DOI":"10.1111\/codi.15295","article-title":"Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy","author":"Musoro","year":"2020","journal-title":"Colorectal Dis."},{"key":"10.1016\/j.lungcan.2022.03.018_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2020.09.007","article-title":"Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core 30 scores in patients with ovarian cancer","author":"Musoro","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.lungcan.2022.03.018_b0160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2018.09.005","article-title":"Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma","volume":"104","author":"Musoro","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2022.03.018_b0165","unstructured":"Z.J. Musoro, C. Coens, F. Fiteni, et al. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with advanced breast cancer. JNCI Cancer Spectrum.pkz037, https:\/\/doi.org\/10.1093\/jncics\/pkz03."},{"key":"10.1016\/j.lungcan.2022.03.018_b0170","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1186\/s12885-021-08609-7","article-title":"Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials","volume":"21","author":"Gamper","year":"2021","journal-title":"BMC Cancer"},{"issue":"21","key":"10.1016\/j.lungcan.2022.03.018_b0175","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1200\/JCO.2003.03.195","volume":"21","author":"Smit","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.03.018_b0180","unstructured":"P. Fayers, N.K. Aaronson, K. Bjordal, M. Groenvold, D. Curran, Bottomley. A on behalf of the EORTC Quality of Life Study Group. EORTC QLQ-C30 Scoring Manual (Third edition). Brussels, EORTC Quality of Life Group, 2001."},{"key":"10.1016\/j.lungcan.2022.03.018_b0185","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Sloan J Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.lungcan.2022.03.018_b0190","doi-asserted-by":"crossref","unstructured":"C.D. Coon. Empirical telling the interpretation story: the case for strong anchors and multiple methods. In: 23rd annual conference of the International Society for Quality of Life Research, Copenhagen, Denmark, October 2016; 2016. p. 1e2. Qual. Life Res. 25(1), ab2.","DOI":"10.1007\/s11136-016-1390-7"},{"key":"10.1016\/j.lungcan.2022.03.018_b0195","article-title":"Establishing anchor-based minimally important differences (MID) with the EORTC quality of life measures: a meta-analysis protocol","volume":"7","author":"Musoro","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.lungcan.2022.03.018_b0200","unstructured":"Institute Inc. 2013. Base SAS\u00ae 9.4 Procedures Guide. Cary, NC: SAS Institute Inc."},{"key":"10.1016\/j.lungcan.2022.03.018_b0205","series-title":"Statistical Power Analysis for the Behavioural Sciences","author":"Cohen","year":"1988"},{"issue":"11","key":"10.1016\/j.lungcan.2022.03.018_b0210","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00520-010-1016-5","article-title":"on behalf of the EORTC PROBE project and the Lung Cancer Group. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials","volume":"19","author":"Maringwa","year":"2011","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.lungcan.2022.03.018_b0215","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.03.018_b0220","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2022.03.018_b0225","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.ejca.2008.05.008","article-title":"Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials","volume":"44","author":"Cocks","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2022.03.018_b0230","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00439229","article-title":"The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30","volume":"5","author":"King","year":"1996","journal-title":"Qual. Life Res."}],"updated-by":[{"DOI":"10.1016\/j.lungcan.2022.05.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000}}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222003877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222003877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T21:37:57Z","timestamp":1673559477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222003877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":46,"alternative-id":["S0169500222003877"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.03.018","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.lungcan.2022.05.006","asserted-by":"object"}]},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma \u2013 Interpretation guidance derived from two randomized EORTC trials","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}